Evidence map›Paper›PMID 35633539›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Expression of miRNA1, miRNA133, miRNA191, and miRNA24, as Good Biomarkers, in Non-Small Cell Lung Cancer Using Real-Time PCR Method.

Mehdi Kazempour Dizaji, Behrooz Farzanegan, Naghmeh Bahrami, Zahra Khoshnam, Mohammad Fathi, Hossein Dargahi, Saviz Pejhan, Adnan Khosravi, Sadegh Shirian, Armita Narimani and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mehdi Kazempour DizajiDepartment of Biostatistics, Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease (NriTlD), Masih Daneshvari Hospital, Shahid Beheshti university of Medical Sciences, Iran.
Behrooz FarzaneganCritical Care Quality Improvement Research Center at Shahid Modarres Hospital, Department of Anaesthesiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Naghmeh BahramiDepartment of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-3575-4094
Zahra KhoshnamAnesthesiology Research Center, Anesthesia and Critical Care Department, Shahid Modares Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad FathiAnesthesiology Research Center, Anesthesia and Critical Care Department, Shahid Modares Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hossein DargahiAllied Medicine, Health information Management research center Tehran university of Medical Sciences, Tehran, Iran.
Saviz PejhanTracheal Diseases Research Center (TDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Adnan KhosraviTobacco Prevention and Control Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sadegh ShirianDepartment of Pathology, School of Veterinary Medicine,Shahrekord University,Shahrekord, Iran.
Armita NarimaniDepartment of Cell and Molecular Biology, School of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Maral EmamiChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahsa RekabiPediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis & Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abdolreza MohamadniaChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer has recently shown the highest incidence among all cancers. microRNAs (miRNAs) are the molecules playing a role in regulating gene expression and contributing to many pathogenic mechanisms. Therefore, these molecules could be used as biomarkers for the detection, anticipation, and treatment of cancer. With this in mind, we decided to investigate and compare the expression of miR-1, miR-133, miR-191, and miR-24 and also the expression differences in these four RNA molecules between lung cancer patients and the controls.

methodsA total of 50 patients with lung cancer participated in this study. In addition, 50 healthy blood samples were selected as the control group. Real-time PCR determined the expression levels of miRNA. The RNAs extracted from the patients' white blood cells were initially synthesized, and then cDNA was extracted. Finally, the synthesized cDNA was amplified using real-time PCR, and its expression was compared with the control group.

resultsThe result indicated a low expression level of miR-1 and miR-133, and a high expression level of miR-191 and miR-24 in the blood of patients with lung cancer compared to the healthy subjects.

conclusionOur findings revealed that miR-1, miR-133, miR-191, and miR-24 are oncogenes, and their expression could result in cancer. It appears that a therapy to overexpress miR-1 and miR-133 and downexpress miR-191 and miR-24 could contribute to the treatment of lung cancer.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMicroRNAsBiomarkers, TumorDNA, ComplementaryHumansReal-Time Polymerase Chain ReactionBiomarkers, TumorDNA, ComplementaryMicroRNAsMIRN133 microRNA, humanMIRN191 microRNA, humanMIRN1 microRNA, humanMIRN24 microRNA, humanmiRNA1miRNA133miRna191 and miRNA24Real-Time PCR

Identifiers

PMID35633539
PMCPMC9587880

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.